- Educatie
- Bron: Campus Sanofi
- 13 dec 2024
The Hematology Podcast - Season 3
Welcome to The Hematology Podcast, your source for the latest insights into hematology and rare blood disorders. This podcast covers cutting-edge research, clinical advancements, and real-world cases tailored for healthcare professionals. Each episode offers expert perspectives on evolving therapies and best practices, helping you stay informed and improve patient outcomes. Whether you're focused on research or clinical practice, The Hematology Podcast is designed to keep you at the forefront of the field, transforming your approach to hematology.
Today we will discuss a rare, inherited metabolic disorder known as ASMD, acid sphingomyelinase deficiency (or historically known as Niemann-Pick types A, A/B, and B). This genetic condition is very rare. It can be diagnosed, after suspicion, by different screening tests. But symptoms may vary greatly, overlap with several other disorders and the road to an accurate diagnosis can therefore be challenging.
In today’s episode we have the pleasure of welcoming Professor David Cassiman to the studio. He is a specialist in hepatology with profound knowledge of metabolic diseases. He currently works at the University Hospital of Leuven (Belgium) where he is the head of the Center for Hereditary Metabolic Diseases. He has spent several years of research, diagnosing, and treating patients with different rare metabolic disorders.
Expert guest
David Cassiman
Professor
Specialist in hepatology
University Hospital of Leuven
Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD).
In this episode we have the pleasure of having the Belgian Assistant professor Dr Amaryllis Van Craenenbroeck with us in the studio. She is Assistant professor at UZ Leuven and specialises in kidney transplantation and kidney diseases. She is board member of different research consortia and societies like for example Chair position in European Renal Association. Prof Van Craenenbroeck is also a frequent speaker at international scientific conferences. She will bring us up to date on recent understandings of the MGRS, how to diagnosed and what symptoms we as hematologists should be aware of.
Expert guest
Dr Amaryllis Van Craenenbroeck
Assistant professor
UZ Leuven and specialises in kidney transplantation and kidney diseases
Today we will discuss a rare, inherited metabolic disorder known as ASMD, acid sphingomyelinase deficiency (or historically known as Niemann-Pick types A, A/B, and B). This genetic condition is very rare. It can be diagnosed, after suspicion, by different screening tests. But symptoms may vary greatly, overlap with several other disorders and the road to an accurate diagnosis can therefore be challenging.
In today’s episode we have the pleasure of welcoming Professor David Cassiman to the studio. He is a specialist in hepatology with profound knowledge of metabolic diseases. He currently works at the University Hospital of Leuven (Belgium) where he is the head of the Center for Hereditary Metabolic Diseases. He has spent several years of research, diagnosing, and treating patients with different rare metabolic disorders.
Expert guest
David Cassiman
Professor
Specialist in hepatology
University Hospital of Leuven
Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD).
In this episode we have the pleasure of having the Belgian Assistant professor Dr Amaryllis Van Craenenbroeck with us in the studio. She is Assistant professor at UZ Leuven and specialises in kidney transplantation and kidney diseases. She is board member of different research consortia and societies like for example Chair position in European Renal Association. Prof Van Craenenbroeck is also a frequent speaker at international scientific conferences. She will bring us up to date on recent understandings of the MGRS, how to diagnosed and what symptoms we as hematologists should be aware of.
Expert guest
Dr Amaryllis Van Craenenbroeck
Assistant professor
UZ Leuven and specialises in kidney transplantation and kidney diseases
Sickle cell disease (SCD) is a hereditary blood disorder, where red blood cells have the shape of a C or sickle - hence the name. Sickle cells have a shorter lifespan than normal red blood cells, which causes anemia. Additionally, sickle cells may block blood vessels, especially during infections, dehydration, stress or fatigue, causing complications for the patients.
Our guest today Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. He is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. His efforts in research have led among others to greater understanding of biomarkers in SCD and complications associated with this disease. In this episode of our Hematology Podcast, Bart will tell us more about SCD, its clinical implications and developments in research which implicate patients today and in the future.
Expert guest
Bart Biemond
Professor
Hematologist
Amsterdam UMC in The Netherlands
Extramedullary disease (EMD) represents an aggressive form of multiple myeloma, characterized by the ability of myeloma cells to form tumors outside the bone marrow independently. Scientific research is continuously evolving, leading to discoveries of new treatments and improvements to current options. However, EMD remains challenging from a therapeutic and biological perspective, and today the prognosis for patients with the disease is generally poor. Experts call for a better understanding of how myeloma cells grow and thrive and about the biology of extramedullary tumors to develop better treatment strategies for the future.
Dr. Elena Zamagni is an expert in this area, and our guest in this episode, all the way from Italy. Dr. Zamagni is an associate professor at the Department of Medical and Surgical Sciences at the University of Bologna and has been a principal investigator in several national and international clinical trials in multiple myeloma.
Expert guest
Dr. Elena Zamagni
Associate professor
Department of Medical and Surgical Sciences at the University of Bologna
Sickle cell disease (SCD) is a hereditary blood disorder, where red blood cells have the shape of a C or sickle - hence the name. Sickle cells have a shorter lifespan than normal red blood cells, which causes anemia. Additionally, sickle cells may block blood vessels, especially during infections, dehydration, stress or fatigue, causing complications for the patients.
Our guest today Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. He is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. His efforts in research have led among others to greater understanding of biomarkers in SCD and complications associated with this disease. In this episode of our Hematology Podcast, Bart will tell us more about SCD, its clinical implications and developments in research which implicate patients today and in the future.
Expert guest
Bart Biemond
Professor
Hematologist
Amsterdam UMC in The Netherlands
Extramedullary disease (EMD) represents an aggressive form of multiple myeloma, characterized by the ability of myeloma cells to form tumors outside the bone marrow independently. Scientific research is continuously evolving, leading to discoveries of new treatments and improvements to current options. However, EMD remains challenging from a therapeutic and biological perspective, and today the prognosis for patients with the disease is generally poor. Experts call for a better understanding of how myeloma cells grow and thrive and about the biology of extramedullary tumors to develop better treatment strategies for the future.
Dr. Elena Zamagni is an expert in this area, and our guest in this episode, all the way from Italy. Dr. Zamagni is an associate professor at the Department of Medical and Surgical Sciences at the University of Bologna and has been a principal investigator in several national and international clinical trials in multiple myeloma.
Expert guest
Dr. Elena Zamagni
Associate professor
Department of Medical and Surgical Sciences at the University of Bologna
Monoclonal gammopathy of undetermined significance, called MGUS, is a blood condition which indicates occurrence of clonal cells that secrete monoclonal immunoglobulins. MGUS as such, is not a harmful disease, and usually doesn’t require treatment. However, every year 1 percent of MGUS patients go on to develop myeloma or lymphoma.
In this episode we have the pleasure of having the Icelandic Professor Sigurdur Kristinsson with us. He specializes in internal medicine and hematology. He has led several large population-based myeloma studies in collaboration with major research centers and is a frequent speaker at international hematology conferences. Professor Kristinsson will bring us up to date on recent understandings of the MGUS condition, what symptoms we as health care professionals should be aware of and how to diagnose today – and what could be possible in the future.
Expert guest
Sigurdur Kristinsson
Professor
Internal medicine and hematology
Waldenström Macroglobulinemia is a rare type of non-Hodgkin lymphoma affecting B-cells. Waldenström Macroglobulinemia is characterised by high levels of circulating antibodies, immunoglobulin M, which is made and secreted by the cells involved in the disease. It is usually an indolent disease with no or limited symptoms. Therefore, patients with Waldenström Macroglobulinemia are often follow closely in “Watchful Waiting” until the disease and symptoms require onset of treatment.
Our guest Ida Bruun Kristensen, hematologist at Odense University Hospital. Ida is an active member in both the Danish Lymphoma Group and Danish Myeloma Study Group as the active in the Nordic clinical societies and is responsible for several ongoing clinical studies. In this episode of our Haematology Podcast Ida enlighten us on Waldenström Macroglobulinemia, its clinical implications and treatment options for the patients today and in the future.
Expert guest
Ida Bruun Kristensen
Hematologist
Odense University Hospital
Monoclonal gammopathy of undetermined significance, called MGUS, is a blood condition which indicates occurrence of clonal cells that secrete monoclonal immunoglobulins. MGUS as such, is not a harmful disease, and usually doesn’t require treatment. However, every year 1 percent of MGUS patients go on to develop myeloma or lymphoma.
In this episode we have the pleasure of having the Icelandic Professor Sigurdur Kristinsson with us. He specializes in internal medicine and hematology. He has led several large population-based myeloma studies in collaboration with major research centers and is a frequent speaker at international hematology conferences. Professor Kristinsson will bring us up to date on recent understandings of the MGUS condition, what symptoms we as health care professionals should be aware of and how to diagnose today – and what could be possible in the future.
Expert guest
Sigurdur Kristinsson
Professor
Internal medicine and hematology
Waldenström Macroglobulinemia is a rare type of non-Hodgkin lymphoma affecting B-cells. Waldenström Macroglobulinemia is characterised by high levels of circulating antibodies, immunoglobulin M, which is made and secreted by the cells involved in the disease. It is usually an indolent disease with no or limited symptoms. Therefore, patients with Waldenström Macroglobulinemia are often follow closely in “Watchful Waiting” until the disease and symptoms require onset of treatment.
Our guest Ida Bruun Kristensen, hematologist at Odense University Hospital. Ida is an active member in both the Danish Lymphoma Group and Danish Myeloma Study Group as the active in the Nordic clinical societies and is responsible for several ongoing clinical studies. In this episode of our Haematology Podcast Ida enlighten us on Waldenström Macroglobulinemia, its clinical implications and treatment options for the patients today and in the future.
Expert guest
Ida Bruun Kristensen
Hematologist
Odense University Hospital
Get to know the host
In each episode, Dr. Mats Merup leads the interviews with the respective experts, providing a deep dive into the clinical, theoretical and practical aspects of the hematological field.
Associate professor Mats Merup, MD PhD (host)
Hematologist
Stockholm, Sweden
Mats Merup is an experienced clinical hematologist with an MD and PhD, specializing in malignant lymphomas and myeloproliferative disorders. He currently works in the clinical setting and has contributed to 50 published research publications as a clinical researcher.
Other channels to subscribe
The Hematology Podcast
Don’t miss the next episode, go to your favorite player and subscribe to the podcast
For additional insights and resources in hematology, refer to the following sites:
Educational programs for healthcare professionals
Educational programs for healthcare professionals
Neem contact op
MAT-BE-2401125 - 1.0 - 12/2024